Who makes Ropivacaine 0.5% 20 mLs?

Ropivacaine 0.5% 20 mLs is developed by Centre Hospitalier Universitaire Vaudois.

What development phase is Ropivacaine 0.5% 20 mLs in?

Ropivacaine 0.5% 20 mLs is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Ropivacaine 0.5% 20 mLs

Centre Hospitalier Universitaire Vaudois · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	Ropivacaine 0.5% 20 mLs
Also known as	Naropine, Naropin
Sponsor	Centre Hospitalier Universitaire Vaudois
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Reducing Pain and Disability After Breast Cancer Surgery (NA)
Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty? (NA)
Serratus and Parasternal Infrapectoral Block for Breast Surgery. (NA)
Dexamethasone as an Adjuvant to Ropivacaine for the Interscalene Brachial Plexus Block (PHASE4)
Local Infiltration Analgesia vs Adductor Canal Block for Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE4)
Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ropivacaine 0.5% 20 mLs CI brief — competitive landscape report
Ropivacaine 0.5% 20 mLs updates RSS · CI watch RSS
Centre Hospitalier Universitaire Vaudois portfolio CI